Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human menopausal gonadotrophin (hMG) is a biologic medication derived from the urine of postmenopausal women, containing both follicle stimulating hormone (FSH) and luteinizing hormone (LH). It is primarily used to treat infertility in women by stimulating ovarian follicular growth, maturation, and ovulation. In men, it is used to stimulate spermatogenesis in cases of hypogonadism. hMG acts by binding to FSH and LH receptors on granulosa and theca cells in the ovary or Leydig cells in the testes, promoting gamete development and steroidogenesis. The drug has been widely used for controlled ovarian stimulation protocols in assisted reproductive technologies such as IVF[1][2][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human menopausal gonadotrophin.